Childhood asthma- an inflammatory disease which exists as many phenotypes and endotypes has a great impact on the life of patients and health workers, especially in its extreme forms. The use of advanced omic technology offers valuable insight into basic asthma endotypes and may provide clinical biomarkers to direct care and progress to a Precision Medication approach. The present article discusses ways in which novel omics methods have affected our current understanding of childhood asthma, as well as the latest results from (pharmaco)genomics, epigenomics, transcriptomics and metabolomics on childhood asthma and its clinical implications.
Omics research has largely extended our understanding of the heterogeneity of asthma, helped to understand cell processes that underlie asthma and helped us more closely to recognise (bio)markers for predicting reaction and progression of diseases. There is a clinical need for biomarkers, especially in the field of biological products, to direct care at individual level. The inclusion of multi omics with clinical information could be a successful next step to developing person risk prediction models for therapy. However, this requires broad, multidisciplinary collaboration.
